The Board of Directors of Sanstar Limited, in their meeting held on May 28, 2026, approved a significant fundraise of ₹198.27 Crores from Corn Products Development Inc.. This investment will be executed through a preferential issue of 1,80,24,157 equity shares at a price of ₹110 per share, granting the investor a 9% stake in the company on a fully diluted basis. Additionally, the Board approved the formation of a joint venture with Ingredion India Private Limited and Amishi Drugs and Chemicals Private Limited, with Sanstar holding a 30% equity stake. Other approved matters include an increase in the authorized share capital to ₹50 Crores, amendments to the Memorandum and Articles of Association to reflect new agreements, and the scheduling of an Extraordinary General Meeting (EGM) on June 20, 2026.

The strategic partnership with Corn Products Development Inc., a subsidiary of the New York Stock Exchange-listed Ingredion Incorporated, marks a major milestone for Sanstar Limited. Under the terms of the Share Subscription Agreement and Shareholders’ Agreement, the investor will gain specific minority protection rights, including the right to nominate one non-independent director to Sanstar’s Board. Furthermore, the newly formed joint venture with Ingredion entities, Spark Ingredients Private Limited, aims to build a scalable specialty ingredients platform in India, focusing on pharmaceuticals, nutraceuticals, and personal care industries.

Sanstar Limited is a prominent player in the manufacturing and processing of plant-based products, including starches and food ingredients. In 2026, the company has focused on expanding its operational footprint and diversifying its business activities to capitalize on market opportunities. By altering its main object clause, Sanstar is positioning itself to broaden its scope into trading and manufacturing a wider array of agricultural, industrial, and pharmaceutical derivative products.

Regarding recent financial performance, the company did not announce quarterly financial results in this specific Board Meeting outcome notice; therefore, no comparative financial analysis or information regarding famous investors is applicable for this reporting period.